June 12, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares over potential securities laws violations by Dicerna Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) concerning whether a series of statements by Dicerna Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) grew from $8.14 per share in November 2014 to as high as $26.94 per share in March 2015.

On June 10, 2015, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that it has filed a trade secret misappropriation lawsuit against Dicerna Pharmaceuticals, Inc. in the Superior Court of Middlesex County, Massachusetts. Alnylam Pharmaceuticals, Inc. said that by this lawsuit, it seeks to stop misappropriation by Dicerna Pharmaceuticals Inc of the company's confidential, proprietary, and trade secret information related to, among other things, GalNAc conjugate technology.